Reaction
Arteriovenous Fistula Site Complication reporting signals
As of the last recalculation, Arteriovenous Fistula Site Complication appears in 597 FAERS reports alongside 10 co-occurring drug terms. The strongest observed disproportionality signal is DARBEPOETIN ALFA (PRR 255.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Darbepoetin Alfa | 238 | 255.3 | 256.5 |
| Epoetin Alfa | 31 | 96.2 | 96.4 |
| Paricalcitol | 28 | 72.5 | 72.6 |
| Cinacalcet Hydrochloride | 31 | 24.4 | 24.4 |
| Iron Sucrose | 6 | 22.2 | 22.2 |
| Sevelamer Carbonate | 7 | 21.5 | 21.5 |
| Eculizumab | 28 | 18.8 | 18.8 |
| Methoxy Polyethylene Glycol-Epoetin Beta | 5 | 15.9 | 15.9 |
| Icodextrin, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride | 8 | 9.1 | 9.1 |
| Patiromer | 3 | 7.6 | 7.6 |